健脾化瘀汤联合肝动脉灌注化疗在肝癌合并门静脉癌栓患者中的应用效果  

Application effect of Jianpi Huayu Decoction combined with hepatic artery infusion chemotherapy in patients with liver cancer combined with portal vein tumor thrombus

作　　者：欧阳兵[1] 冯引凤 陈江华 刘金明[1] OUYANG Bing;FENG Yinfeng;CHEN Jianghua;LIU Jinming(Department of Liver Tumor,the Ninth Hospital of Nanchang,Jiangxi Province,Nanchang 330002,China)

机构地区：[1]南昌市第九医院肝脏肿瘤科,江西南昌330002

出　　处：《中国当代医药》2025年第4期75-78,83,共5页China Modern Medicine

基　　金：江西省中医药管理局科技计划项目(2022A12)。

摘　　要：目的探讨健脾化瘀汤联合肝动脉灌注化疗(HAIC)在肝癌合并门静脉癌栓患者中的应用效果。方法回顾性分析2022年1月至2023年12月南昌市第九医院收治的40例原发性肝癌合并门静脉癌栓患者的临床资料,按照是否服用中药分为观察组(20例)与对照组(20例)。两组患者均行介入治疗,并采取HAIC治疗;在此基础上,观察组服用健脾化瘀汤。比较两组患者的不良反应、卡诺夫斯凯计分(KPS)、肝功能水平、疗效。结果观察组的血细胞下降、胃肠道反应、发热的发生率均低于对照组,差异有统计学意义(P<0.05);两组患者的肝区疼痛发生率比较,差异无统计学意义(P>0.05)。治疗后,观察组的KPS评分高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组的丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)和总胆红素(TBil)水平均低于对照组,差异有统计学意义(P<0.05)。两组患者的客观缓解率(ORR)、疾病控制率(DCR)比较,差异无统计学意义(P>0.05)。结论健脾化瘀汤联合HAIC具有较高的安全性,造成肝功能损伤更小,为中晚期肝癌提供更好的治疗方法,值得临床推广。Objective To investigate the application effect of Jianpi Huayu Decoction combined with hepatic artery infusion chemotherapy(HAIC)in patients with liver cancer combined with portal vein tumor thrombus.Methods The clinical data of 40 patients with primary liver cancer and portal vein tumor thrombus admitted to the Ninth Hospital of Nanchang from January 2022 to December 2023 were retrospectively analyzed.According to whether they took traditional Chinese medicine,they were divided into observation group(20 cases)and control group(20 cases).Both groups were treated with interventional therapy and HAIC.On this basis,the observation group was given Jianpi Huayu Decoction.The adverse reactions,Kanofsky performance score(KPS),liver function and efficacy were compared between the two groups.Results The incidences of hemocytopenia,gastrointestinal reaction and fever in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of liver pain between the two groups(P>0.05).After treatment,the KPS score of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of alanine transaminase(ALT),aspartate transaminase(AST)and total bilirubin(TBil)in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in objective response rate(ORR)and disease control rate(DCR)between the two groups(P>0.05).Conclusion Jianpi Huayu Decoction combined with HAIC has high safety,causes less liver function damage,and provides a better treatment method for advanced liver cancer,which is worthy of clinical promotion.

关 键 词：中药 肝动脉灌注化疗 肝癌 门静脉癌栓 

分 类 号：R735.7[医药卫生—肿瘤]